There was no significant difference in ixazomib IC50 values between the DH/DEL group and the non-DH/DEL groups (p = 0.5288; Figure 1D), nor was there a difference between the mutant p53 and wild-type p53 groups (p = 0.6416; Figure 1E), suggesting that ixazomib is also effective in poor responder DLBCL groups. Here, TP53 is linked to diffuse large B-cell lymphoma.